Is this email not displaying correctly? View it in your browser.
Newswise - News for Journalists
Newswise Special Wire
Tuesday, June 6, 2017

Public edition |

Newswise Cancer Research Wire for 06-Jun-2017

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

Gut Bacteria Could Protect Cancer Patients and Pregnant Women From Listeria, Study Suggests

Researchers at Memorial Sloan Kettering Cancer Center in New York have discovered that bacteria living in the gut provide a first line of defense against severe Listeria infections. The study, which will be published June 6 in The Journal of Experime...

– The Rockefeller University Press

Journal of Experimental Medicine, July 2017; K23 AI095398-01; RO1 AI42135; U01 AI124275-01; P30 CA008748

Embargo expired on 06-Jun-2017 at 09:00 ET

Warren Alpert Foundation Honors Five Pioneers in Cancer Immunology

Scientists recognized for seminal discoveries in cancer’s ability to thwart immune surveillance that paved the way to immune-based cancer therapies

– Harvard Medical School

New Target Found to Attack an Incurable Brain Tumor in Children

A study published in Molecular Cancer Research reveals that a tumor suppressor gene p16 is turned off by a histone mutation (H3.3K27M), which is found in up to 70 percent of childhood brain tumors called diffuse intrinsic pontine glioma (DIPG). This ...

– Ann & Robert H. Lurie Children's Hospital of Chicago

Molecular Cancer Research, May 2017

Researchers Report Encouraging Results From Combination Therapy in Hodgkin Lymphoma

The authors of a phase II clinical study report that combination therapy with brentuximab vedotin and gemcitabine in patients is “highly active" regimen for patients with Hodgkin lymphoma.

– Roswell Park Cancer Institute

Research Study Gives New Insight Into How Cancer Spreads

A research study led by University of Minnesota engineers gives new insight into how cancer cells move based on their ability to sense their environment. The discovery could have a major impact on therapies to prevent the spread of cancer. The same r...

– University of Minnesota College of Science and Engineering

Nature Communications, May 22, 2017

Dasatinib Excels in Worldwide Phase II Trial Against Pediatric CML

Worldwide phase II clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 show the promise of the second-generation drug dasatinib against pediatric CML. Of 113 pediatric patients studied, 75 percent...

– University of Colorado Cancer Center

ASCO 2017

Embargo expired on 05-Jun-2017 at 08:00 ET

CONNECT Registry Shows Only 9 Percent Compliance with Genetic Testing Guidelines for Aml

Study presented at ASCO 2017 shows that only 9 percent of 259 evaluated AML patients received all seven of the NCCN-recommended genetic tests.

– University of Colorado Cancer Center

ASCO 2017

Embargo expired on 05-Jun-2017 at 08:00 ET

SWOG Clinical Trials Added More Than 3M Years of Life for Cancer Patients, Fred Hutch Researcher Reports

For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute-funded SWOG clinical trials program has added 3.34 million years of life for cancer patients in the United States because of successful therapies th...

– Fred Hutchinson Cancer Research Center

2017 ASCO Annual Meeting

Embargo expired on 05-Jun-2017 at 17:45 ET

Study Finds Rate of Mastectomies Decreases with Adoption of Breast Tumor Margin Guidelines: What This Means in the Overtreatment Debate for Breast Cancer

In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study be...

– Memorial Sloan Kettering Cancer Center

JAMA Oncology; ASCO Annual Meeting

Embargo expired on 05-Jun-2017 at 10:45 ET

Higher Gut Bacteria Diversity Tied to Slower Metastatic Melanoma Progression

The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center report at the 2017 a...

– University of Texas M. D. Anderson Cancer Center

Embargo expired on 05-Jun-2017 at 14:15 ET

Phase I Study Advances New Option for Urothelial Cancers

A recent study by Yale Cancer Center researchers revealed a 41% response to the antibody drug, enfortumab vedotin, by metastatic urothelial (mUC) tumors in a phase I clinical trial

– Yale Cancer Center

Black, White Men View Impacts of Prostate Cancer Treatment Differently, Study Finds

UNC Lineberger Comprehensive Cancer Center surveyed 1,171 men diagnosed with prostate cancer in North Carolina, finding that while both white and black men were concerned about curing their cancer and the quality-of-life impacts of treatment, more bl...

– University of North Carolina Health Care System

Advanced quantum dots shed bright light on biological processes

Precise fluorescent imaging at the molecular level has not been possible because of non-specific fluorescence by surrounding tissues. Now researchers have resolved many of these problems by using SWIR quantum dots in live mice to image working orga...

– National Institute of Biomedical Imaging and Bioengineering

Nat Biomed Eng, Apr-2017; EB015871

Study: Collateral Damage from Cosmic Rays Increases Cancer Risks for Mars Astronauts

The cancer risk for a human mission to Mars has effectively doubled following a UNLV study predicting a dramatic increase in the disease for astronauts traveling to the red planet or on long-term missions outside the protection of Earth's magnetic fi...

– University of Nevada, Las Vegas (UNLV)

Scientific Reports, May 2017

Penn Effort to Expand Trials of Olaparib Leads to New Treatment Options for Patients with Advanced BRCA-Related Breast Cancer

Six years ago an international team of physician scientists known as BRCA-TAC led a charge to advance clinical testing of the PARP inhibitor olaparib in cancer patients with known inherited mutations in BRCA1 and BRCA2. This weekend during the plenar...

– Perelman School of Medicine at the University of Pennsylvania

2017 ASCO Annual Meeting

Embargo expired on 04-Jun-2017 at 06:30 ET

Real-Time, Patient-Reported Symptom Monitoring Demonstrates an Overall Survival Benefit

Updated results of a clinical trial that launched in 2007 were presented today by Ethan Basch, MD, of Memorial Sloan Kettering Cancer Center (MSK) and UNC Lineberger Comprehensive Cancer Center, at the annual meeting of the American Society of Clinic...

– Memorial Sloan Kettering Cancer Center


Embargo expired on 04-Jun-2017 at 07:30 ET

Phase III Trial of PARP Inhibitor Shows First Evidence of Improved Outcomes in Breast Cancer

The first phase III trial of a PARP inhibitor used to treat breast cancer reported promising data at the annual meeting of the American Society of Clinical Oncology (ASCO). Mark Robson, MD, Clinic Director of the Clinical Genetics Service and medical...

– Memorial Sloan Kettering Cancer Center


Embargo expired on 04-Jun-2017 at 07:30 ET

Two Combination Therapies Shrink Melanoma Brain Metastases in More Than Half of Patients

A combination regimen of two immunotherapies and another of two targeted therapies each significantly shrank metastatic brain tumors in at least 50 percent of patients in separate multi-center clinical trials presented today at the 2017 ASCO Annual M...

– University of Texas M. D. Anderson Cancer Center

2017 ASCO Annual Meeting

Embargo expired on 04-Jun-2017 at 10:00 ET

Immunotherapy Drug Effective for Metastatic Triple Negative Breast Cancer

Immunotherapy trial in metastatic triple negative breast cancer patients proves to shrink tumors in patients.

– NYU Langone Medical Center

ASCO Annual Meeting Jun-2017

Embargo expired on 03-Jun-2017 at 16:50 ET

Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from ...

– Memorial Sloan Kettering Cancer Center

ASCO meeting #LBA2501

Embargo expired on 03-Jun-2017 at 07:30 ET

Novel Sequencing Approach Seeks to Detect Cancer’s Genomic Alterations

Findings from an early study evaluating a sophisticated new genomic-sequencing approach that analyzes cell-free DNA (cfDNA) in the blood of people with advanced cancer will help inform development of a future assay that could potentially detect cance...

– Memorial Sloan Kettering Cancer Center

ASCO Annual Meeting LBA11516

Embargo expired on 03-Jun-2017 at 07:30 ET

Genetic Sequencing Could Influence Treatment for Nearly Three-Quarters of Advanced Cancer Patients

A new analysis finds that nearly three-quarters of 500 patients with advanced cancer could be referred to a potential targeted treatment based on the results of a comprehensive analysis of their tumor’s genetic landscape.

– Michigan Medicine - University of Michigan

American Society of Clinical Oncology Annual Meeting June 2017; 1UM1HG006508; CA214170; CA186786

Immunotherapy Combination Shows Promise in Early Stage Triple Negative Breast Cancer

Immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as a preoperative treatment shows promise in early stage TNBC.

– Yale Cancer Center

Combination Therapy Targets Genetic Mutation Found in Many Cancers

A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused by a mutation of the RAS gene found in many cancers. The pre-clinical study combined therapies targeting the in...

– University of Texas M. D. Anderson Cancer Center

Men: Start Your Path to a Healthier You with 7 Tips

Physicians at UAB share tips on men’s health and how it affects heart health, sexual function and memory and decreases cancer risk.

– University of Alabama at Birmingham

Five Years Before Brain Cancer Diagnosis, Changes Detectable in Blood

Changes in immune activity appear to signal a growing brain tumor five years before symptoms arise, new research has found.

– Ohio State University

Embargo expired on 01-Jun-2017 at 14:00 ET

Minority Breast Cancer Patients Less Likely to Have Genetic Test

A genetic test that helps doctors determine how best to treat breast cancer—and whether chemotherapy is likely to help—is significantly more likely to be administered to white women than blacks or Hispanics, a Yale study has found.

– Yale Cancer Center

Payments Linked to Higher Odds of Doctors Prescribing Certain Cancer Drugs

In preliminary findings (abstract 6510) that will be presented at the American Society of Clinical Oncology Annual Meeting 2017 in Chicago on Saturday, June 3, researchers show that when physicians had to choose between multiple, on-patent drugs for ...

– University of North Carolina Health Care System

2017 ASCO Annual Meeting

Tip Sheet: Immunotherapy Trial Results for Cancer Among Research Presentations by Johns Hopkins Scientists

Combining two checkpoint inhibitors, drugs that remove inhibitory signals and restore the immune system’s ability to fight cancer, may be effective in shrinking melanoma tumors or preventing their growth in some patients who previously received sta...

– Johns Hopkins Medicine

Immune Responses From Early Study of Novel Sarcoma Vaccine

The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects. The findings will be presented by Dr. Seth Pollack, a physician-scientist at Fred Hutc...

– Fred Hutchinson Cancer Research Center

ASCO (American Society of Clinical Oncology)

Immunotherapy with DNA Vaccine Shows Promise for HPV-Related Head and Neck Cancer

A novel vaccine therapy can generate immune responses in patients with head and neck squamous cell carcinoma (HNSCCa), according to researchers at the Abramson Cancer Center of the University of Pennsylvania. The treatment specifically targets human ...

– Perelman School of Medicine at the University of Pennsylvania

2017 ASCO Annual Meeting; NCI-5P30 CA016520-39

Combined Modality Treatment Could Be First Course of Treatment for Muscle-Invasive Bladder Cancer, New Study Shows

A meta-analysis of previously published cancer research showed no difference in five-year and 10-year survival rates between patients who underwent radical cystectomy, which is the surgical removal of the bladder, and a bladder-preserving combined mo...

– American Society for Radiation Oncology (ASTRO)

International Journal of Radiation Oncology, Biology, Physics, Apr-2017

Personalized Cell Therapy Combined with Ibrutinib Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients

Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman S...

– Perelman School of Medicine at the University of Pennsylvania

2017 ASCO Annual Meeting

Moffitt Develops Innovative Approaches to Improve Personalized Radiation Therapy for Head and Neck Cancer Patients

Moffitt researchers have developed a test called the radiosensitivity index that determines how sensitive a patient’s tumor is to radiation therapy. The radiosensitivity index is based on the expression of different genes in a patient’s tumor and...

– Moffitt Cancer Center

The Lancet

Possible Correlation Shown Between the Partial Meltdown at TMI and Thyroid Cancers

Penn State College of Medicine researchers have shown, for the first time, a possible correlation between the partial meltdown of the Three Mile Island Nuclear Generating Station and thyroid cancers in the counties surrounding the plant.

– Penn State College of Medicine


Precancerous Lesions Associated with HPV Dropping in Connecticut, YSPH Study Finds

The vaccine for HPV is proving to have significant population-level effects in Connecticut, a new Yale School of Public Health study finds.

– Yale Cancer Center

Clinical Trial Shows Experimental Drug’s Ability to Knock Down Pancreatic Cancer’s Defense

By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, accor...

– Fred Hutchinson Cancer Research Center

ASCO Annual Meeting, June, 2017

Ludwig Researchers Present New Findings on Combination Immunotherapy and Other Research at the 2017 ASCO Annual Meeting

Ludwig Cancer Research released today the full scope of Ludwig’s participation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6.

– Ludwig Cancer Research

ASCO Annual Meeting

Study Makes Breakthrough in Understanding of Proteins and Their Impact on Immune System

Researchers at the University of Birmingham have made a breakthrough in the understanding of how our genetic make-up can impact on the activity of the immune system and our ability to fight cancer.

– University of Birmingham

Science Signaling, May-2017

Embargo expired on 30-May-2017 at 15:00 ET

Patients’ Fear of Socioeconomic Profiling, Doctors’ Conflicts of Interest Are Barriers to Cost Transparency in Cancer Care

Being transparent about the cost of cancer treatments with patients has been increasingly recommended to help minimize financial harm and improve care, but what’s preventing or derailing those conversations is less understood. New findings from Pen...

– Perelman School of Medicine at the University of Pennsylvania

2017 American Society of Clinical Oncology Annual Meeting

Many Cancer Patients’ Emergency Department Visits Appear Preventable, Fred Hutch Study Finds

As many as 53 percent of cancer patients’ Emergency Department visits that do not require admission could be avoided with better symptom management and greater availability of outpatient care tailored to their needs, according to a new study from F...

– Fred Hutchinson Cancer Research Center

2017 ASCO Annual Meeting, June 2017

Triple Immunotherapy for Rare Skin Cancer Shows Promise in Small, Early-Stage Trial

Combo of T-cell therapy, newly FDA-approved drug and another immunotherapeutic agent kept cancer at bay for three out of four patients with metastatic Merkel cell carcinoma. The findings will be presented June 5 at the annual meeting of the American ...

– Fred Hutchinson Cancer Research Center

American Society of Clinical Oncology

New Prostate Cancer Technology Improves Biopsy Accuracy

New prostate cancer technology is improving the accuracy of biopsies. The technique fuses information from a prostate MRI to ultrasound images taken during the biopsy. The technique results in higher cancer detection, fewer biopsies and more accurate...

– Loyola University Health System


Four Dana-Farber Researchers Awarded Prestigious “Outstanding Investigator Awards” by National Cancer Institute

The National Cancer Institute (NCI) has awarded four Dana-Farber Cancer Institute researchers with Outstanding Investigator Awards (OIA) for ongoing progressive research within their respective areas of study.

– Dana-Farber Cancer Institute

Facial Nerve Clinic to Provide Comprehensive Personalized Care

A multidisciplinary team will provide patients with advanced technology to diagnose and manage facial nerve disorders.

– University of Alabama at Birmingham

Fred & Pamela Buffett Cancer Center is dedicated in Omaha

New cancer center has been under construction for nearly four years; features extensive Healing Arts Program highlighted by Chihuly Sanctuary, designed by world-renowned glass artist, Dale Chihuly

– University of Nebraska Medical Center (UNMC)

Cancer Research Institute Hosts Fifth Annual Cancer Immunotherapy Month™ in June to Celebrate Progress in Cancer Research and Patient Treatment

Cancer Immunotherapy Month in June to feature educational and awareness programming for patients, caregivers, and the public

– Cancer Research Institute

What’s Next? NCCN Gathers Health Care Policy Experts to Deliberate Challenges to Patient Safety and Access to Cancer Care under the New Administration

The NCCN Policy Summit: Ensuring Patient Access and Safety in Cancer Care takes place on Thursday, June 15, 2017, from 9:30 am – 3:00 pm at the National Press Club in Washington, DC.

– National Comprehensive Cancer Network® (NCCN®)

Johns Hopkins and Eisai Extend Drug Discovery Collaboration with New Licensing Agreement

The Johns Hopkins University and Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., announced today that they have extended their drug discovery collaboration through an exclusive licensing agreement.

– Johns Hopkins Medicine

Embargo expired on 31-May-2017 at 08:00 ET

Penn Medicine’s Carl June, MD, to Receive ASCO’s Highest Scientific Honor

The American Society of Clinical Oncology has named University of Pennsylvania cancer and HIV gene therapy pioneer Carl June, MD, as the 2017 winner of the David A. Karnofsky Memorial Award. The honor goes to an oncologist who has made outstanding co...

– Perelman School of Medicine at the University of Pennsylvania

2017 ASCO Annual Meeting

NCCN and CancerLinQ Collaborating to Provide Evidence-Based, Decision-Making Resources to Physicians

New Collaboration Will Grant CancerLinQ Subscribers Streamlined Access to the NCCN Compendium®

– National Comprehensive Cancer Network® (NCCN®)

Dana-Farber Cancer Institute Names Lesley Solomon SVP, Chief Innovation Officer

Dana-Farber Cancer Institute has named Lesley Solomon to the newly-created position of senior vice president for innovation and chief innovation officer. Solomon has been serving as executive director of the Brigham Innovation Hub at Brigham and Wome...

– Dana-Farber Cancer Institute

Powerhouse Medical Oncologist Joins UAB as Director of the UAB Comprehensive Cancer Center

Michael J. Birrer, M.D., Ph.D., a leading medical oncologist and trailblazer in the early detection and treatment of gynecologic cancers, has been named director of the University of Alabama at Birmingham Comprehensive Cancer Center.

– University of Alabama at Birmingham

Promising New Treatment for Pancreatic Cancer Comes to Orlando Health

Oncologists at UF Health Cancer Center Orlando Health are deploying NanoKnife® as a new weapon in the battle against pancreatic cancer.

– Orlando Health

GW Researcher Receives $1.2M Grant to Standardize Cancer Genomics Data

Raja Mazumder, Ph.D., at GW School of Medicine and Health Sciences received a NIH grant to develop databases to normalize cancer genomics data.

– George Washington University

Expert Pitch

Treatment of EGFR Mutant Non-Small Cell Lung Cancer

– Yale Cancer Center

Slaying the Sleeping Dragon: Researchers Take Action Against Breast Cancer Recurrence

– Perelman School of Medicine at the University of Pennsylvania

Yale Cancer Center Researcher Receives Funding From the American Cancer Society for Research Into BRCA2

– Yale Cancer Center

Yale Expert Discusses Ways to Lower Your Skin Cancer Risk

– Yale Cancer Center

Northwestern Medicine Experts Available to speak on Presentations at the 2017 ASCO Annual Meeting

– Northwestern Medicine


New Studies Help Colon Cancer Survivors Stay Cancer-Free

The American Cancer Society estimates more than 95,000 Americans will be diagnosed with colon cancer this year. Dr. Charles Fuchs at Yale Cancer Center discusses way to prevent the disease.

– Yale Cancer Center





 Edit My Preferences
 Contact Us
 Newswise Home
 Newswise Contact Directory
 Expert Queries
 Presspass Application

More News from:

 University of Birmingham

 The Rockefeller University Press

 Penn State College of Medicine

 University of Alabama at Birmingham

 Michigan Medicine - University of Michigan

 University of Texas M. D. Anderson Cancer Center

 University of Minnesota College of Science and Engineering

 George Washington University

 Northwestern Medicine

Subscribe / Unsubscribe
Edit my preferences

© 2017 Newswise, Inc. All Rights Reserved.

215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417

 Contact Us